GENET-news
To stay informed you can subscribe to the GENET-news list.
2009-04-07 | permalink
U.S. drug firm drops GE safflower insulin option offered by SemBioSys
A Los Angeles-area drug company that paid for a year-long option to license the rights to [SemBioSys’] plant-produced insulin has let the option lapse. [...] MannKind’s decision follows its announcement March 9 that it would buy drug giant Pfizer’s insulin facility at Frankfurt, Germany for US$33 million, including a license to make bulk insulin there for its rapid-acting pulmonary insulin product, Afresa.
- Country Guide, Canada: U.S. drug firm drops safflower insulin option
- SemBioSys, Canada: SemBioSys provides update on insulin program
- MannKind, USA: MannKind agrees with Pfizer on the purchase of Frankfurt insulin manufacturing plant
- SemBioSys, Canada: SemBioSys Genetics Inc. announces clinical results with plant-produced insulin
Overview
News
2009-04-07 | permalink
U.S. drug firm drops GE safflower insulin option offered by SemBioSys
A Los Angeles-area drug company that paid for a year-long option to license the rights to [SemBioSys’] plant-produced insulin has let the option lapse. [...] MannKind’s decision follows its announcement March 9 that it would buy drug giant Pfizer’s insulin facility at Frankfurt, Germany for US$33 million, including a license to make bulk insulin there for its rapid-acting pulmonary insulin product, Afresa.
- Country Guide, Canada: U.S. drug firm drops safflower insulin option
- SemBioSys, Canada: SemBioSys provides update on insulin program
- MannKind, USA: MannKind agrees with Pfizer on the purchase of Frankfurt insulin manufacturing plant
- SemBioSys, Canada: SemBioSys Genetics Inc. announces clinical results with plant-produced insulin
GENET-news & GENET-forum
GENET-news is providing a daily news service on a range of topics regarding genetic engineering. We are screening the worldwide English news, press releases and other publications to provide you with a strategic selection of information. GENET-news enables you to stay informed about all aspects of the global controversy around GE technologies and GE organisms. You can subscribe by 
email.
The GENET-forum list provides you with additional background information and more voluminous reports. It is only open for GENET members. Please contact the coordinator for membership and subscription.